Validation of an Allergic Rhinitis Control Test in Children

NCT03075917 | Recruiting DMC

• 1 other identifier: RECHMPL16_0283
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 6

Brief Summary

Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in teenagers or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitis (ARCT) in patients from 12 years of age. We propose to adapt ARCT adult to pediatric population from 5 to 11 years old.

Conditions

Allergic Rhinitis

Keywords

Allergic rhinitis

Outcome Measures

Primary Outcomes (1)

• Score of the allergic rhinitis control self questionnaire

  Score of the allergic rhinitis control self questionnaire in teenagers from 5 to 11 years old.

  15 days

Study Arms (1)

Experimental

EXPERIMENTAL

questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days

Other: Self Questionnaire

Interventions

Self Questionnaire OTHER

self questionnaire for allergic rhinitis control

Experimental

Eligibility Criteria

• Age: 5 Years - 11 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Patients aged 5 to 11 years old, consulting a practitioner for an allergic rhinitis
• Parents formulated their study participation agreement by signing the consent form.

You may not qualify if:

• Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatment.

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (6)

CH Louis Pasteur

Bagnols-sur-Cèze, France

COMPLETED

Maison de santé de Lasalle

Lasalle, 30460, France

TERMINATED

CH de MILLAU

Millau, France

COMPLETED

Centre (Ctre) Medical Ravas - Malbosc

Montpellier, 34080, France

COMPLETED

University hospital of Montpellier

Montpellier, 34295, France

RECRUITING

Hôpital Trousseau,

Paris, France

COMPLETED

MeSH Terms

Conditions

Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Pascal DEMOLY, Professor

CONTACT

+334 67 33 61 27; pascal.demoly@inserm.fr

Anca CHIRIAC, MD

CONTACT

a-chiriac@chu-montpellier.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2017
• First Posted: March 9, 2017
• Study Start: May 4, 2017
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: January 5, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

FR (6)